logo-loader

Feedback advancing clinical use of TexRAD after bagging CE mark

Published: 01:05 24 Nov 2017 AEDT

Alastair Riddell, chairman of Feedback plc (LON:FDBK) tells Proactive they're now able to crack on with expanding the clinical use of  TexRAD in the treatment of lung cancer across the EU after finally receiving a CE mark for the technology earlier this week.

The award of the CE mark means Feedback can now sell TexRAD Lung to hospitals, satisfying the quality, safety and performance standards required for medical devices in the European Union.

This particular version of the product will help doctors diagnose and treat people with lung cancer, the most common and most deadly form of the disease.

OzAurum to start drilling at Boca Rica Lithium Project

OzAurum Resources Ltd (ASX:OZM) CEO and managing director Andrew Pumphrey sits down with Proactive’s Jonathan Jackson to discuss an upcoming drilling program at Boca Rica Lithium Project in Brazil, following the identification of a spodumene zone. The company plans to start drilling in the next...

4 hours, 16 minutes ago